Cantor Fitzgerald keeps USD 18 target for Surgery Partners stock

Published on 10/20/2026 at 19:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 848.90 million on June 30, 2026. Surgery Partners stock costs EUR 13.70 on October 20, 2026 at Lang & Schwarz.

Target and operating figures

Cantor Fitzgerald kept an USD 18.00 target and Overweight rating on October 6, 2026.
Second-quarter revenue reached USD 848.90 million for the period ended June 30, 2026.
Surgery Partners stock was trading at EUR 13.70 at Lang & Schwarz on October 20, 2026 at 7:12 p.m. CEST.

SGRY, US86881A1007, Illustration mit AI erstellt.

Surgery Partners (ISIN US86881A1007) was priced at USD 15.38 on Nasdaq on October 20, 2026 at 1:21 p.m. ET, while Cantor Fitzgerald maintained an Overweight rating and an USD 18.00 target on October 6, 2026, according to Investing.com. The target was 17.04 percent above the Nasdaq quote. The euro price was EUR 13.70 at Lang & Schwarz on October 20, 2026 at 7:12 p.m. CEST.

Revenue reached USD 848.90 million

Surgery Partners reported USD 848.90 million in second-quarter revenue for the period ended June 30, 2026. That was 4.69 percent above the USD 810.90 million recorded in the first quarter, based on the company figures available in its investor-relations materials. The company also reported a USD 15.00 million net loss and adjusted earnings per share of negative USD 0.12 for the second quarter.

Operating profit reached USD 102.10 million in the second quarter, compared with USD 65.80 million in the first quarter. Operating cash flow was USD 59.30 million in the second quarter, up from USD 11.70 million in the first quarter. The second-quarter results and the September 17, 2026 guidance update are listed by Surgery Partners.

Stock remains below its yearly high

The Nasdaq quote of USD 15.38 stood within a 52-week range of USD 11.41 to USD 23.44 on October 20, 2026 at 1:21 p.m. ET. The price was 34.39 percent below the yearly high. Surgery Partners had a market capitalization of USD 2.0 billion on October 20, 2026.

The company operates more than 300 surgical locations in 30 states, including ambulatory surgery centers, surgical hospitals, physician practices and urgent care facilities. Its business combines Surgical Facility Services with Ancillary Services, giving revenue growth a direct link to procedure volumes and related care.

What the target means for valuation

Cantor Fitzgerald's USD 18.00 target leaves a 17.04 percent gap above the USD 15.38 Nasdaq quote. The October 6, 2026 rating was a reaffirmation rather than a new target level, making the distance to the target the clearest analyst reference for investors today.

Price and operating picture

The second-quarter revenue increase of 4.69 percent from the first quarter came alongside a narrower net loss of USD 15.00 million versus USD 35.90 million. The figures place the stock's valuation discussion alongside operating cash flow of USD 59.30 million for the second quarter.

Surgery Partners was trading at EUR 13.70 at Lang & Schwarz on October 20, 2026 at 7:12 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Surgery Partners stock.